JP2016512259A5 - - Google Patents

Download PDF

Info

Publication number
JP2016512259A5
JP2016512259A5 JP2016500760A JP2016500760A JP2016512259A5 JP 2016512259 A5 JP2016512259 A5 JP 2016512259A5 JP 2016500760 A JP2016500760 A JP 2016500760A JP 2016500760 A JP2016500760 A JP 2016500760A JP 2016512259 A5 JP2016512259 A5 JP 2016512259A5
Authority
JP
Japan
Prior art keywords
methyl
chlorophenyl
difluoromethoxy
methoxypyridin
triazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016500760A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016512259A (ja
JP6282721B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/021426 external-priority patent/WO2014158998A1/en
Publication of JP2016512259A publication Critical patent/JP2016512259A/ja
Publication of JP2016512259A5 publication Critical patent/JP2016512259A5/ja
Application granted granted Critical
Publication of JP6282721B2 publication Critical patent/JP6282721B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016500760A 2013-03-14 2014-03-06 Pde4阻害剤としての置換ピリジン及びピラジン化合物 Active JP6282721B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361786288P 2013-03-14 2013-03-14
US61/786,288 2013-03-14
PCT/US2014/021426 WO2014158998A1 (en) 2013-03-14 2014-03-06 Substituted pyridine and pyrazine compounds as pde4 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018009464A Division JP6505878B2 (ja) 2013-03-14 2018-01-24 Pde4阻害剤としての置換ピリジン及びピラジン化合物

Publications (3)

Publication Number Publication Date
JP2016512259A JP2016512259A (ja) 2016-04-25
JP2016512259A5 true JP2016512259A5 (enExample) 2017-04-06
JP6282721B2 JP6282721B2 (ja) 2018-02-21

Family

ID=51530139

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016500760A Active JP6282721B2 (ja) 2013-03-14 2014-03-06 Pde4阻害剤としての置換ピリジン及びピラジン化合物
JP2018009464A Active JP6505878B2 (ja) 2013-03-14 2018-01-24 Pde4阻害剤としての置換ピリジン及びピラジン化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018009464A Active JP6505878B2 (ja) 2013-03-14 2018-01-24 Pde4阻害剤としての置換ピリジン及びピラジン化合物

Country Status (17)

Country Link
US (8) US20160009691A1 (enExample)
EP (2) EP2970212B1 (enExample)
JP (2) JP6282721B2 (enExample)
KR (1) KR102232221B1 (enExample)
CN (2) CN105143207B (enExample)
AU (2) AU2014241430B2 (enExample)
BR (1) BR112015022474B1 (enExample)
CA (1) CA2895209C (enExample)
DK (1) DK3345902T3 (enExample)
ES (1) ES2769181T3 (enExample)
IL (1) IL240804B (enExample)
MX (1) MX370188B (enExample)
NZ (1) NZ711587A (enExample)
RU (1) RU2668073C2 (enExample)
SG (2) SG10201703405PA (enExample)
TW (2) TWI623523B (enExample)
WO (1) WO2014158998A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6282721B2 (ja) * 2013-03-14 2018-02-21 ダート・ニューロサイエンス・(ケイマン)・リミテッド Pde4阻害剤としての置換ピリジン及びピラジン化合物
EP3519816A4 (en) 2016-09-29 2020-05-06 The Regents of the University of California CONNECTIONS FOR INCREASING NEURONAL PLASTICITY
US20210145838A1 (en) * 2018-04-05 2021-05-20 Universiteit Hasselt Selective pde4d inhibitors against demyelinating diseases
CN109438434B (zh) * 2018-11-19 2021-05-04 华南农业大学 一种含噁唑环的2-氰基亚氨基噻唑烷类化合物及其制备方法和应用
MX2021010198A (es) 2019-02-27 2021-09-21 Univ California Indoles n-sustituidos y otros heterociclos para el tratamiento de trastornos cerebrales.
KR102946120B1 (ko) 2019-02-27 2026-03-30 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 뇌 장애를 치료하기 위한 아제피노-인돌 및 다른 헤테로사이클
EP3959203A1 (en) * 2019-04-23 2022-03-02 Tetra Discovery Partners, Inc. 3-hydroxy-2-phenyl-6-(pyrazol-4-ylmethyl)pyridine derivatives as pde4d inhibitors
CN114072143A (zh) * 2019-05-06 2022-02-18 钙医学公司 Crac通道抑制剂的合成
KR20220082092A (ko) * 2019-11-07 2022-06-16 스몰 파마 엘티디 화합물
US12404265B2 (en) 2020-08-04 2025-09-02 Nura Bio, Inc. Substituted pyridine derivatives as SARM1 inhibitors
CN111995585B (zh) * 2020-08-04 2022-01-25 常州大学 嘧啶乙酰胺类化合物及其作为磷酸二酯酶pde2活性抑制剂的应用
CN116438171A (zh) 2020-09-16 2023-07-14 努拉生物公司 作为sarm1抑制剂的取代的吡啶衍生物
CA3198798A1 (en) 2020-11-13 2022-05-19 Kenneth Stauderman Improved synthesis of crac channel inhibitors
EP4376840A4 (en) 2021-07-28 2025-05-21 Nura Bio, Inc. SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS
IL313455A (en) 2021-12-15 2024-08-01 Delix Therapeutics Inc Phenoxy and benzyloxy modified psychroplastogens and their uses
CN116265440B (zh) * 2021-12-16 2024-09-27 贵州大学 一种水杨酮拼接吡啶酮类化合物及其制备方法及应用
EP4562001A1 (en) * 2022-07-27 2025-06-04 Nura Bio, Inc. Substituted pyridine derivatives as sarm1 inhibitors
WO2024067660A1 (zh) 2022-09-29 2024-04-04 苏州爱科百发生物医药技术有限公司 氮杂稠环类化合物、其制备方法及其在医药上的应用
CN116082254B (zh) * 2022-12-28 2025-04-11 浙江永太科技股份有限公司 一种1-烷基-1,2,4-三氮唑-3-甲醇的制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
AU1504599A (en) 1997-12-17 1999-07-05 Shionogi & Co., Ltd. Novel pyridine compounds
US7868015B2 (en) 2000-08-10 2011-01-11 Cold Spring Harbor Laboratory Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
US9931318B2 (en) 2003-04-08 2018-04-03 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
EP2316531A1 (en) 2000-08-10 2011-05-04 Cold Spring Harbor Laboratory Augmented cognitive training
GB0111078D0 (en) 2001-05-04 2001-06-27 Novartis Ag Organic compounds
AR037517A1 (es) 2001-11-05 2004-11-17 Novartis Ag Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
AR037714A1 (es) 2001-12-06 2004-12-01 Maxia Pharmaceuticals Inc Derivados de tiazolidinona y oxazolidinona 2-sustituidos para la inhibicion de fosfatasas y el tratamiento de cancer
CA2506297A1 (en) 2002-11-19 2004-06-03 Memory Pharmaceuticals Corporation Pyridine n-oxide compounds as phosphodiesterase 4 inhibitors
GB0229281D0 (en) 2002-12-16 2003-01-22 Novartis Ag Organic compounds
US20050020587A1 (en) 2003-07-25 2005-01-27 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
MY141255A (en) 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
KR101267392B1 (ko) * 2004-06-30 2013-05-23 주식회사 씨앤드씨신약연구소 피리딘 유도체 및 그의 제조방법
GB0425572D0 (en) 2004-11-19 2004-12-22 Glaxo Group Ltd 1,7-Naphthyridines
WO2006124874A2 (en) * 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
BRPI0708337A2 (pt) 2006-02-28 2011-05-24 Helicon Therapeutics Inc pipirazinas terapêutica como inibidores pde4
NZ570847A (en) 2006-02-28 2011-10-28 Helicon Therapeutics Inc Therapeutic compounds
WO2007123953A2 (en) * 2006-04-19 2007-11-01 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
RS51163B (sr) 2006-04-19 2010-10-31 Boehringer Ingelheim International Gmbh. Dihidrotienopirimidin za lečenje zapaljenskih bolesti
JP5440934B2 (ja) 2006-05-24 2014-03-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換プテリジン
KR101107896B1 (ko) * 2006-10-04 2012-01-25 에프. 호프만-라 로슈 아게 고 밀도 지단백질(hdl)-콜레스테롤 상승제로서 3-피리딘카복스아마이드 및 2-피라진카복스아마이드 유도체
BRPI0811623A2 (pt) 2007-05-15 2014-11-11 Helicon Therapeutics Inc Métodos para identificar genes envolvidos na formação de memória usando pequeno rna interferente (sirna)
KR101669432B1 (ko) 2007-08-27 2016-10-26 다트 뉴로사이언스 (케이만) 엘티디. 치료적 이속사졸 화합물
US8877816B2 (en) 2007-11-21 2014-11-04 Decode Genetics Ehf 4-(or 5-) substituted catechol derivatives
US20090130076A1 (en) 2007-11-21 2009-05-21 Decode Genetics Ehf Substituted benzoazole pde4 inhibitors for treating pulmonary and cardiovascular disorders
JP2011504505A (ja) 2007-11-21 2011-02-10 デコード ジェネティクス イーエイチエフ 肺および心血管障害を治療するためのビアリールpde4抑制剤
EP2222638A2 (en) * 2007-11-21 2010-09-01 Decode Genetics EHF Biaryl pde4 inhibitors for treating inflammation
US20100029689A1 (en) 2008-07-02 2010-02-04 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
WO2010056195A1 (en) 2008-11-14 2010-05-20 Astrazeneca Ab New compounds 575
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
US9394290B2 (en) 2010-10-21 2016-07-19 Universitaet Des Saarlandes Campus Saarbruecken Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases
JP6282721B2 (ja) 2013-03-14 2018-02-21 ダート・ニューロサイエンス・(ケイマン)・リミテッド Pde4阻害剤としての置換ピリジン及びピラジン化合物

Similar Documents

Publication Publication Date Title
JP2016512259A5 (enExample)
RU2015137615A (ru) Замещенные пиридиновые и пиразиновые соединения в качестве ингибиторов pde4
JP2014528446A5 (enExample)
RU2019118623A (ru) Пирролопиримидины в качестве потенциаторов мвтр
JP2007523182A5 (enExample)
JP2017500364A5 (enExample)
DK2491038T3 (da) Disubstituerede octahydropyrrolo [3,4-c]pyrroler som orexin receptormodulatorer
ES2642766T3 (es) Compuestos heterocíclicos conocidos y nuevos como agentes para combatir plagas
JP2019504854A5 (enExample)
JP2018524331A5 (enExample)
RU2012146246A (ru) Антибактериальные производные изохинолин-3-илмочевины
JP2013508403A5 (enExample)
JP2013518046A5 (enExample)
HRP20220096T1 (hr) Inhibitori lizin specifične demetilaze-1
JP2018535999A5 (enExample)
JP2016514718A5 (enExample)
JP2014531465A5 (enExample)
JP2015514072A5 (enExample)
JP2017502049A5 (enExample)
JP2014518214A5 (enExample)
RU2012133475A (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
JP2015528022A5 (enExample)
IL187690A (en) Derivatives 1, 2, 4 - Triazolo - 1, 6 - Naphthiridines as inhibitors of AKT activity for use in the preparation of drugs for the treatment of cancer
SI2763982T1 (en) Substituted benzylindazoles for use as inhibitors of Bub kinase in the treatment of hyperproliferative diseases
JP2014521711A5 (enExample)